Royalty Report: Drugs, Disease – Collection: 275832


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275832

License Grant
With the original agreement, the Licensor confers an exclusive,  license to practice and use the Intellectual Property and all Improvements thereon in order to make, use, or sell the Products, for all uses and in all applications and indications within North America.  The second amendment add royalty information.
License Property
The Products shall mean the pharmaceutical products developed by or on behalf of the Company, currently identified by the Company as TheraCLEC Totalâ„¢, and any derivatives thereof, which contain the  crystaline  enzyme lipase and either or both of the crystaline  enzyme protease. and amylase, and which are, in either case, designed to treat pancreatic insufficiency in cystic fibrosis patients.
Field of Use
This agreement is to collaborate with respect to the farther development, testing, and marketing of a new drug developed by the Company to treat pancreatic insufficiency in cystic fibrosis patients in North America.

IPSCIO Record ID: 172763

License Grant
Licensor grants an exclusive license within the Territory to use, offer for sale and sell the Products. Licensee acknowledges that its license as it relates to Product A is a semi-exclusive license subject to a previous license granted to another party for the territory.
License Property
The products are gastro-protected pancreatin compositions containing the Active Ingredient, a mixture of lipases, proteases and amylases, and certain excipients, said composition being produced by Licensor and meeting the Specifications.  Those Products having USP Lipase contents of 4,500 and 10,000, all of which are included in the definition of Products.

Licensor is the owner of original processes and know-how for the manufacture of sustained release pharmaceutical substances.

Pancrelipase, a pancreatic enzyme used primarily by cystic fibrosis patents to aid in digestion, for the generic market.

Field of Use
This agreement is for the pharmaceutical industry.

IPSCIO Record ID: 266853

License Grant
Licensor grants the German Licensee a non-transferable, exclusive license, with the right to sublicense, under the Licensed Product Patents to develop, commercialize, market, sell and distribute, but not manufacture, the Licensed Product in the Field in the Territory.

Licensor grants a non~exclusive, non•transferable license, with the right to sublicense, to use the Licensors Mark solely within the Territory and solely in connection with the sale of the Licensed Product in the Field.

License Property
The Licensed Product shall mean any pharmaceutical form, dosage, strength, or formulation of TheraCLEC-Total purchased from Licensor.

TheraCLEC-Total shall mean commercial formulations of that product currently known as TheraCLEC-Total consisting of the enzymes, lipase, amylase and protease.

Field of Use
The Field shall mean the treatment of symptoms (e.g. malabsorption or pain) directly caused by exocrine pancreatic insufficiency.  TheraCLEC is a novel orally delivered enzyme replacement therapy that is intended to replace digestive enzymes in patients suffering from pancreatic insufficiency.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.